Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (327)	8/7/1999 2:33:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

Weisbrod puts a nice little personal stamp on biotech in this article........ exchange2000.com Very nicely done, including this........ Q: Is MEDI a one-trick pony? A: No. It has a very strong early-stage pipeline that is focusing on treatments for autoimmune diseases, other anti-infectives and a number of vaccines. Six drugs are in clinical development. If any one of them succeeds, it could add another $150 million-$200 million product to MEDI's arsenal. Again, the royalty (if and when) is nice, with no flow through...... BTRN does not cover the responsibility for Belgium.